HRP20150520T1 - Supstituirani 2-okso- i 2-tiokso-dihidrokinolin-3-karboksamidi kao modulatori kcnq2/3 - Google Patents
Supstituirani 2-okso- i 2-tiokso-dihidrokinolin-3-karboksamidi kao modulatori kcnq2/3 Download PDFInfo
- Publication number
- HRP20150520T1 HRP20150520T1 HRP20150520TT HRP20150520T HRP20150520T1 HR P20150520 T1 HRP20150520 T1 HR P20150520T1 HR P20150520T T HRP20150520T T HR P20150520TT HR P20150520 T HRP20150520 T HR P20150520T HR P20150520 T1 HRP20150520 T1 HR P20150520T1
- Authority
- HR
- Croatia
- Prior art keywords
- aliphatic residue
- residue
- unsubstituted
- aliphatic
- methyl
- Prior art date
Links
- HUJZMVIORDMFRP-UHFFFAOYSA-N 2-sulfanylidene-3,4-dihydro-1h-quinoline-3-carboxamide Chemical class C1=CC=C2NC(=S)C(C(=O)N)CC2=C1 HUJZMVIORDMFRP-UHFFFAOYSA-N 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 claims 162
- 125000001424 substituent group Chemical group 0.000 claims 60
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 60
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 52
- 150000001408 amides Chemical class 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 16
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 13
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000001544 thienyl group Chemical group 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 150000007513 acids Chemical class 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- FGWFNQOJRGTOQX-UHFFFAOYSA-N 1-ethyl-n-[(4-methoxyphenyl)methyl]-4-methyl-2-oxoquinoline-3-carboxamide Chemical compound O=C1N(CC)C2=CC=CC=C2C(C)=C1C(=O)NCC1=CC=C(OC)C=C1 FGWFNQOJRGTOQX-UHFFFAOYSA-N 0.000 claims 1
- UAZGSOAEFVKLAS-UHFFFAOYSA-N 2-[3-[(3-fluorophenyl)-methylcarbamoyl]-4-methyl-2-oxo-7-(trifluoromethyl)quinolin-1-yl]acetic acid Chemical compound CC=1C2=CC=C(C(F)(F)F)C=C2N(CC(O)=O)C(=O)C=1C(=O)N(C)C1=CC=CC(F)=C1 UAZGSOAEFVKLAS-UHFFFAOYSA-N 0.000 claims 1
- DNNYYSRNGNCOBH-UHFFFAOYSA-N 3-[3-[(3-fluorophenyl)-methylcarbamoyl]-4-methyl-2-oxo-7-(trifluoromethyl)quinolin-1-yl]propanoic acid Chemical compound CC=1C2=CC=C(C(F)(F)F)C=C2N(CCC(O)=O)C(=O)C=1C(=O)N(C)C1=CC=CC(F)=C1 DNNYYSRNGNCOBH-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- UOZJSAIWWICINH-UHFFFAOYSA-N C(CC)N1C(C(=C(C2=CC=CC=C12)C)C(=O)NCC1=CC=C(C=C1)OC)=O Chemical compound C(CC)N1C(C(=C(C2=CC=CC=C12)C)C(=O)NCC1=CC=C(C=C1)OC)=O UOZJSAIWWICINH-UHFFFAOYSA-N 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- MRQLPJPRQPAECU-UHFFFAOYSA-N methyl 2-[3-[(3-fluorophenyl)-methylcarbamoyl]-4-methyl-2-oxo-7-(trifluoromethyl)quinolin-1-yl]acetate Chemical compound O=C1N(CC(=O)OC)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)N(C)C1=CC=CC(F)=C1 MRQLPJPRQPAECU-UHFFFAOYSA-N 0.000 claims 1
- BMSWURAYDALHTO-UHFFFAOYSA-N methyl 3-[3-[(3-fluorophenyl)-methylcarbamoyl]-4-methyl-2-oxo-7-(trifluoromethyl)quinolin-1-yl]propanoate Chemical compound O=C1N(CCC(=O)OC)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)N(C)C1=CC=CC(F)=C1 BMSWURAYDALHTO-UHFFFAOYSA-N 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- VWBNNHGQKSAWNY-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-1,4-dimethyl-2-oxo-7-(trifluoromethoxy)quinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC(OC(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 VWBNNHGQKSAWNY-UHFFFAOYSA-N 0.000 claims 1
- BRNALIDKFTXKHL-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-1,4-dimethyl-2-oxo-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 BRNALIDKFTXKHL-UHFFFAOYSA-N 0.000 claims 1
- OSIDCNSMTUAOLA-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-1-(1-methoxybutan-2-yl)-4-methyl-2-oxo-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(C(COC)CC)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 OSIDCNSMTUAOLA-UHFFFAOYSA-N 0.000 claims 1
- TXSCTNNFGFMUPX-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-1-(1-methoxypropan-2-yl)-4-methyl-2-oxo-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(C(C)COC)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 TXSCTNNFGFMUPX-UHFFFAOYSA-N 0.000 claims 1
- APSDBKYLIHXEMW-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-1-(2-hydroxyethyl)-4-methyl-2-oxo-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(CCO)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 APSDBKYLIHXEMW-UHFFFAOYSA-N 0.000 claims 1
- NZFMRHPTCPWFRT-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-1-(2-methoxybutyl)-4-methyl-2-oxo-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(CC(CC)OC)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 NZFMRHPTCPWFRT-UHFFFAOYSA-N 0.000 claims 1
- XPANITDISRRBCJ-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-1-(2-methoxyethyl)-4-methyl-2-oxo-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(CCOC)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 XPANITDISRRBCJ-UHFFFAOYSA-N 0.000 claims 1
- GNBIHQVYSMQSPM-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-1-(2-methoxyethyl)-4-methyl-2-oxoquinoline-3-carboxamide Chemical compound O=C1N(CCOC)C2=CC=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 GNBIHQVYSMQSPM-UHFFFAOYSA-N 0.000 claims 1
- UHEDLTCEYYYHAO-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-1-(2-methoxypropyl)-4-methyl-2-oxo-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(CC(C)OC)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 UHEDLTCEYYYHAO-UHFFFAOYSA-N 0.000 claims 1
- IFRBPIJTDKBDNA-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-1-(3-methoxypropyl)-4-methyl-2-oxo-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(CCCOC)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 IFRBPIJTDKBDNA-UHFFFAOYSA-N 0.000 claims 1
- AXAMKIBEFDQNRZ-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-1-methyl-2-oxo-4-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC=CC=C2C(C(F)(F)F)=C1C(=O)NCC1=CC=CC(F)=C1 AXAMKIBEFDQNRZ-UHFFFAOYSA-N 0.000 claims 1
- LAEPCGOURMGXAN-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methoxy-1-methyl-2-oxo-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(C)C2=CC(C(F)(F)F)=CC=C2C(OC)=C1C(=O)NCC1=CC=CC(F)=C1 LAEPCGOURMGXAN-UHFFFAOYSA-N 0.000 claims 1
- PHBTWZGLXJGJCR-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-1-(3-methylbutyl)-2-oxo-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(CCC(C)C)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 PHBTWZGLXJGJCR-UHFFFAOYSA-N 0.000 claims 1
- TVRJGISEVUPWGL-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-1-(4-methylpentyl)-2-oxo-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(CCCC(C)C)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 TVRJGISEVUPWGL-UHFFFAOYSA-N 0.000 claims 1
- GCJZFDLSPBEJND-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-1-(oxan-4-yl)-2-oxo-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(C2CCOCC2)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 GCJZFDLSPBEJND-UHFFFAOYSA-N 0.000 claims 1
- DXKCYGKPDJWVDH-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-2-oxo-1-pentyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(CCCCC)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 DXKCYGKPDJWVDH-UHFFFAOYSA-N 0.000 claims 1
- HQPVSOGMSTVSAP-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-2-oxo-1-propan-2-yl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(C(C)C)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 HQPVSOGMSTVSAP-UHFFFAOYSA-N 0.000 claims 1
- QUFAZPCEDHNYMA-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-2-oxo-1-propyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(CCC)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 QUFAZPCEDHNYMA-UHFFFAOYSA-N 0.000 claims 1
- BHYZZERRWQHFDV-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-1,4-dimethyl-2-sulfanylidene-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound S=C1N(C)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 BHYZZERRWQHFDV-UHFFFAOYSA-N 0.000 claims 1
- SCYSVEBNNZJWMJ-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-1-(2-methoxyethyl)-4-methyl-2-oxo-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound O=C1N(CCOC)C2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 SCYSVEBNNZJWMJ-UHFFFAOYSA-N 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- -1 racemates Chemical class 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
Claims (15)
1. Supstituirani spoj opće formule (I)
[image]
pri čemu
X označava O ili S,
R1 predstavlja C1-10-alifatski ostatak, nesupstituiran ili mono- ili polisupstituiran C3-10-cikloalifatski ostatak, nesupstituiran ili mono- ili polisupstituiran i proizvoljno premošten preko C1-8 alifatske skupine, koja zauzvrat može biti nesupstituirana ili mono- ili polisupstituirana; aril ili heteroaril, svaki puta nesupstituiran ili mono- ili polisupstituiran i svaki puta proizvoljno premošten preko C1-8 alifatske skupine, koja zauzvrat može biti nesupstituirana ili mono- ili polisupstituirana;
R2 predstavlja F; Cl; Br; I; CN; CF3; C(=O)H; NO2; OCF3; SCF3; C1-4-alifatski ostatak, C(=O)-C1-4 alifatski ostatak, C(=O)-O-C1-4 alifatski ostatak, C(=O)-NH-C1-4 alifatski ostatak, C(=O)-N(C1-4 alifatski ostatak)2, pri čemu C1-4 alifatski ostatak može svaki puta biti nesupstituiran ili mono- ili polisupstituiran; O-C1-4-alifatski ostatak, O-C(=O)-C1-4-alifatski ostatak, S-C1-4-alifatski ostatak, S(=O)2-C1-4-alifatski ostatak, S(=O)2-O-C1-4-alifatski ostatak, pri čemu C1-4 alifatski ostatak može svaki puta biti nesupstituiran ili mono- ili polisupstituiran; C3-6-cikloalifatski ostatak ili 3 do 6 člani heterocikloalifatski ostatak, svaki puta nesupstituiran ili mono- ili polisupstituiran i svaki puta proizvoljno premošten preko C1-4 alifatske skupine, koja zauzvrat može biti nesupstituirana ili mono- ili polisupstituirana;
R3, R4, R5 i R6 svaki neovisno jedan od drugoga predstavljaju H; F; Cl; Br; I; CN; CF3; C(=O)H; C(=O)-OH; C(=O)-NH2; SCF3; S(=O)2-OH; NO2; OCF3; C1-4-alifatski ostatak, C(=O)-C1-4 alifatski ostatak, C(=O)-O-C1-4 alifatski ostatak, C(=O)-NH-C1-4 alifatski ostatak, C(=O)-N(C1-4 alifatski ostatak)2, pri čemu C1-4 alifatski ostatak može svaki puta biti nesupstituiran ili mono- ili polisupstituiran; O-C1-4-alifatski ostatak, O-C(=O)-C1-4-alifatski ostatak, S-C1-4-alifatski ostatak, S(=O)2-C1-4-alifatski ostatak, S(=O)2-O-C1-4-alifatski ostatak, pri čemu C1-4 alifatski ostatak može svaki puta biti nesupstituiran ili mono- ili polisupstituiran; NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, NH-C(=O)-C1-4 alifatski ostatak, NH-S(=O)2-C1-4-alifatski ostatak, N(C1-4 alifatski ostatak)-C(=O)-C1-4 alifatski ostatak, ili N(C1-4 alifatski ostatak)-S(=O)2-C1-4 alifatski ostatak, pri čemu C1-4 alifatski ostatak može svaki puta biti nesupstituiran ili mono- ili polisupstituiran; C3-6-cikloalifatski ostatak ili 3 do 6 člani heterocikloalifatski ostatak, svaki puta nesupstituiran ili mono- ili polisupstituiran i svaki puta proizvoljno premošten preko C1-4 alifatske skupine, koja zauzvrat može biti nesupstituirana ili mono- ili polisupstituirana;
R7 predstavlja C1-10-alifatski ostatak, nesupstituiran ili mono- ili polisupstituiran; C3-10-cikloalifatski ostatak ili 3 do 10 člani heterocikloalifatski ostatak, svaki puta nesupstituiran ili mono- ili polisupstituiran i svaki puta proizvoljno premošten preko C1-8 alifatske skupine, koja zauzvrat može biti nesupstituirana ili mono- ili polisupstituirana;
pod uvjetom da ako R7 označava 3 do 10 člani heterocikloalifatski ostatak, 3 do 10 člani heterocikloalifatski ostatak je vezan preko ugljikovog atoma,
u kojem "alifatska skupina" i "alifatski ostatak" mogu svaki puta biti razgranati ili nerazgranati, zasićeni ili nezasićeni,
u kojem "cikloalifatski ostatak" i "heterocikloalifatski ostatak" mogu svaki puta biti zasićeni ili nezasićeni,
u kojem se "mono- ili polisupstituiran" s obzirom na "alifatsku skupinu" i "alifatski ostatak" odnosi, s obzirom na odgovarajuće ostatke ili skupine, na supstituciju jednog ili više vodikovih atoma svakog međusobno neovisno s najmanje jednim supstituentom odabranim iz skupine koju čine F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), NH-C(=O)-C1-4 alifatski ostatak, NH-S(=O)2-C1-4 alifatski ostatak, OH, OCF3, O-C1-4-alifatski ostatak, O-C(=O)-C1-4-alifatski ostatak, SH, SCF3, S-C1-4-alifatski ostatak, S(=O)2OH, S(=O)2-C1-4-alifatski ostatak, S(=O)2-O-C1-4-alifatski ostatak, S(=O)2-NH-C1-4-alifatski ostatak, CN, CF3, CHO, COOH, C1-4-alifatski ostatak, C(=O)-C1-4-alifatski ostatak, C(=O)-O-C1-4-alifatski ostatak, C3-6-cikloalifatski ostatak, 3 do 6 člani heterocikloalifatski ostatak, C(=O)-NH2, C(=O)-NH(C1-4 alifatski ostatak), te C(=O)-N(C1-4 alifatski ostatak)2;
u kojem se "mono- ili polisupstituiran" s obzirom na "cikloalifatski ostatak" i "heterocikloalifatski ostatak" odnosi, s obzirom na odgovarajuće ostatke, na supstituciju jednog ili više vodikovih atoma svakog međusobno neovisno s najmanje jednim supstituentom odabranim iz skupine koju čine F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, NH-C(=O)-C1-4 alifatski ostatak, NH-S(=O)2-C1-4 alifatski ostatak, =O, OH, OCF3, O-C1-4-alifatski ostatak, O-C(=O)-C1-4-alifatski ostatak, SH, SCF3, S-C1-4-alifatski ostatak, S(=O)2OH, S(=O)2-C1-4-alifatski ostatak, S(=O)2-O-C1-4-alifatski ostatak, S(=Oh-NH-C1-4-alifatski ostatak, CN, CF3, CHO, COOH, C1-4-alifatski ostatak, C(=O)-C1-4-alifatski ostatak, C(=O)-O-C1-4-alifatski ostatak, C3-6-cikloalifatski ostatak, 3 do 6 člani heterocikloalifatski ostatak, C(=O)-NH2, C(=O)-NH(C1-4 alifatski ostatak), te C(=O)-N(C1-4 alifatski ostatak)2;
u kojem se "mono- ili polisupstituiran" s obzirom na "aril" i "heteroaril" odnosi, s obzirom na odgovarajuće ostatke, na supstituciju jednog ili više vodikovih atoma svakog međusobno neovisno s najmanje jednim supstituentom odabranim iz skupine koju čine F, Cl, Br, I, NO2, NH2,
[image]
NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, NH-C(=O)-C1-4 alifatski ostatak, NH-S(=O)2-C1-4 alifatski ostatak, OH, OCF3, O-C1-4-alifatski ostatak, O-C(=O)-C1-4-alifatski ostatak, SH, SCF3, S-C1-4-alifatski ostatak, S(=O)2OH, S(=O)2-C1-4-alifatski ostatak, S(=O)2-O-C1-4-alifatski ostatak, S(=O)2-NH-C1-4-alifatski ostatak, CN, CF3, C(=O)H, C(=O)OH, C1-4-alifatski ostatak, C(=O)-C1-4-alifatski ostatak, C(=O)-O-C1-4-alifatski ostatak, C3-6-cikloalifatski ostatak, 3 do 6 člani heterocikloalifatski ostatak, benzil, aril, heteroaril, C(=O)-NH2, C(=O)-NH(C1-4 alifatski ostatak), te C(=O)-N(C1-4 alifatski ostatak)2;
s izuzetkom slijedećih spojeva: 1-etil-N-(4-metoksibenzil)-4-metil-2-okso-1,2-dihidrokinolin-3-karboksamida, te 1-propil-N-(4-metoksibenzil)-4-metil-2-okso-1,2-dihidrokinolin-3-karboksamida
u obliku slobodnih spojeva, racemata, enantiomera, dijastereomera, smjesa enantiomera ili dijastereomera u bilo kojem omjeru miješanja, ili pojedinačnog enantiomera ili dijastereomera, ili u obliku soli fiziološki prihvatljivih kiselina ili baza.
2. Spoj prema zahtjevu 1, naznačen time da
R1 označava C1-10-alifatski ostatak, nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), OH, O-C1-4-alifatski ostatak, OCF3, SH, SCF3, S-C1-4-alifatski ostatak, CF3, CN, C1-4-alifatski ostatak i C(=O)-OH,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, OCF3, CF3 i nesupstituiran O-C1-4-alifatski ostatak,
ili označava C3-10-cikloalifatski ostatak, nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, OH, =O, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak, C(=O)-OH, C3-6 cikloalifatski ostatak, te 3 do 6 člani heterocikloalifatski ostatak,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, OCF3, CF3 i nesupstituiran O-C1-4-alifatski ostatak, te
pri čemu C3-6 cikloalifatski ostatak i 3 do 6 člani heterocikloalifatski ostatak može svaki puta biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, OH, =O, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak i C(=O)-OH,
i pri čemu C3-10-cikloalifatski ostatak može biti proizvoljno premošten preko C1-8 alifatske skupine, koja zauzvrat može biti nesupstituirana ili mono- ili polisupstituirana s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, OH, =O, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak i C(=O)-OH,
ili označava aril ili heteroaril, svaki puta nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, OH, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak, C(=O)-OH, C(=O)-CH3, C(=O)-C2H5, C(=O)-O-CH3 i C(=O)-O-C2H5, C3-6 cikloalifatski ostatak, 3 do 6 člani heterocikloalifatski ostatak,
[image]
benzil, fenil, tienil, piridil, furil, tiazolil i oksazolil,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, OCF3, CF3 i nesupstituiran O-C1-4-alifatski ostatak, te
pri čemu benzil, fenil, tienil, piridil, furil, tiazolil i oksazolil može svaki puta biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, OH, O-C1-4 alifatski ostatak, OCF3, O-CH2-OH, O-CH2-O-CH3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak, C(=O)-OH, C(=O)-CH3, C(=O)-C2H5, C(=O)-O-CH3 i C(=O)-O-C2H5, i
pri čemu C3-6 cikloalifatski ostatak i 3 do 6 člani heterocikloalifatski ostatak može svaki puta biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, OH, =O, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak i C(=O)-OH,
i pri čemu arilni ili heteroarilni ostatak može svaki puta biti proizvoljno premošten preko C1-8 alifatske skupine, koja zauzvrat može biti nesupstituirana ili mono- ili polisupstituirana s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), OH, O- C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN i C(=O)-OH,
X predstavlja O ili S;
R2 predstavlja F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; C1-4-alifatski ostatak, S-C1-4-alifatski ostatak, O-C1-4-alifatski ostatak, pri čemu C1-4 alifatski ostatak može svaki puta biti nesupstituiran ili mono- ili polisupstituiran; C3-6-cikloalifatski ostatak ili 3 do 6 člani heterocikloalifatski ostatak, svaki puta nesupstituiran ili mono- ili polisupstituiran i svaki puta proizvoljno premošten preko C1-4 alifatske skupine, koja zauzvrat može biti nesupstituirana ili mono- ili polisupstituirana,
R3, R4, R5 i R6 svaki neovisno jedan od drugoga predstavljaju H; F; Cl; Br; I; CN; CF3; OCF3; SCF3; C(=O)H; C(=O)-OH; C(=O)-NH2; S(=O)2-OH; NO2; C1-4-alifatski ostatak, C(=O)-C1-4 alifatski ostatak, C(=O)-O-C1-4 alifatski ostatak, C(=O)-NH-C1-4 alifatski ostatak, C(=O)-N(C1-4 alifatski ostatak)2, O-C1-4-alifatski ostatak, O-C(=O)-C1-4-alifatski ostatak, S-C1-4-alifatski ostatak, S(=O)2-C1-4-alifatski ostatak, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, NH-C(=O)-C1-4 alifatski ostatak, i NH-S(=O)2-C1-4-alifatski ostatak, pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, i O-C1-4-alifatski ostatak; C3-6-cikloalifatski ostatak ili 3 do 6 člani heterocikloalifatski ostatak, svaki puta nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, C1-4-alifatski ostatak i O-C1-4-alifatski ostatak, te svaki puta proizvoljno premošten preko nesupstituirane C1-4 alifatske skupine,
R7 označava C1-10-alifatski ostatak, nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), OH, O-C1-4-alifatski ostatak, OCF3, SH, SCF3, S-C1-4-alifatski ostatak, CF3, CN, C1-4-alifatski ostatak, C(=O)-O-C1-4-alifatski ostatak i C(=O)-OH,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, OCF3, CF3 i nesupstituiran O-C1-4-alifatski ostatak,
ili označava C3-10-cikloalifatski ostatak ili 3 do 10 člani heterocikloalifatski ostatak, svaki puta nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, OH, =O, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak, C(=O)-OH, C3-6 cikloalifatski ostatak, te 3 do 6 člani heterocikloalifatski ostatak,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, OCF3, CF3 i nesupstituiran O-C1-4-alifatski ostatak, te
pri čemu C3-6 cikloalifatski ostatak i 3 do 6 člani heterocikloalifatski ostatak može svaki puta biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, OH, =O, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak i C(=O)-OH,
i pri čemu C3-10-cikloalifatski ostatak ili 3 do 10 člani heterocikloalifatski ostatak može svaki puta biti proizvoljno premošten preko C1-8 alifatske skupine, koja zauzvrat može biti nesupstituirana ili mono- ili polisupstituirana s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), OH, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak i C(=O)-OH,
pod uvjetom da ako R7 označava 3 do 10 člani heterocikloalifatski ostatak, 3 do 10 člani heterocikloalifatski ostatak je vezan preko ugljikovog atoma.
3. Spoj prema zahtjevu 1 ili 2, naznačen time da
R2 predstavlja F; Cl; Br; I; CN; CF3; NO2; OCF3; SCF3; C1-4-alifatski ostatak, S-C1-4-alifatski ostatak, O-C1-4-alifatski ostatak,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, i nesupstituiran O-C1-4-alifatski ostatak,
C3-6-cikloalifatski ostatak ili 3 do 6 člani heterocikloalifatski ostatak, svaki puta nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, =O, OH, C1-4-alifatski ostatak i O-C1-4-alifatski ostatak,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, i nesupstituiran O-C1-4-alifatski ostatak,
i pri čemu C3-6-cikloalifatski ostatak ili 3 do 6 člani heterocikloalifatski ostatak može svaki puta biti proizvoljno premošten preko C1-4 alifatske skupine, koja zauzvrat može biti nesupstituirana ili mono- ili polisupstituirana s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, nesupstituiran C1-4-alifatski ostatak i nesupstituiran O-C1-4-alifatski ostatak.
4. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da
R3, R4, R5 i R6 svaki neovisno jedan od drugoga predstavljaju H; F; Cl; Br; I; CN; CF3; OCF3; SCF3; C(=O)H; C(=O)-OH; C(=O)-NH2; S(=O)2-OH; NO2; C1-4-alifatski ostatak, C(=O)-C1-4 alifatski ostatak, C(=O)-O-C1-4 alifatski ostatak, O-C1-4-alifatski ostatak, O-C(=O)-C1-4-alifatski ostatak, S-C1-4-alifatski ostatak, S(=O)2-C1-4-alifatski ostatak, pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, i O-C1-4-alifatski ostatak; C3-6-cikloalifatski ostatak ili 3 do 6 člani heterocikloalifatski ostatak, svaki puta nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, =O, OH, C1-4-alifatski ostatak i O-C1-4-alifatski ostatak, te svaki puta proizvoljno premošten preko nesupstituirane C1-4 alifatske skupine.
5. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da
R3, R4, R5 i R6 svaki neovisno jedan od drugog su izabrani iz skupine koja sadrži H; F; Cl; Br; I; NO2; CF3; CN; OCF3; SCF3; (C=O)-C1-4 alifatski ostatak, C1-4 alifatski ostatak, O-C1-4 alifatski ostatak, S- C1-4 alifatski ostatak, pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, i O-CH3.
6. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da najmanje jedan od R3, R4, R5 i R6 je ≠ H.
7. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da
R1 predstavlja parcijalnu strukturu (T1)
[image]
pri čemu
m označava 0, 1, 2, 3 ili 4,
R8a i R8b svaki neovisno jedan od drugoga predstavljaju H, F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), OH, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4 alifatski ostatak ili C(=O)-OH,
R8c označava C1-4 alifatski ostatak, nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), OH, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak i C(=O)-OH,
ili označava C3-10-cikloalifatski ostatak, nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, OH, =O, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak, C(=O)-OH, C3-6 cikloalifatski ostatak i 3 do 6 člani heterocikloalifatski ostatak,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, OCF3, CF3 i nesupstituiran O-C1-4-alifatski ostatak, i
pri čemu C3-6 cikloalifatski ostatak i 3 do 6 člani heterocikloalifatski ostatak može svaki puta biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, OH, =O, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak i C(=O)-OH,
ili označava aril ili heteroaril, svaki puta nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, OH, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak, C(=O)-OH, C(=O)-CH3, C(=O)-C2H5, C(=O)-O-CH3 i C(=O)-O-C2H5, C3-6 cikloalifatski ostatak, 3 do 6 člani heterocikloalifatski ostatak,
[image]
benzil, fenil, tienil, piridil, furil, tiazolil i oksazolil,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, OCF3, CF3 i nesupstituiran O-C1-4-alifatski ostatak, i
pri čemu benzil, fenil, tienil, piridil, furil, tiazolil i oksazolil može svaki puta biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, OH, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak, C(=O)-OH, C(=O)-CH3, C(=O)-C2H5, C(=O)-O-CH3 i C(=O)-O-C2H5, i
pri čemu C3-6 cikloalifatski ostatak i 3 do 6 člani heterocikloalifatski ostatak može svaki puta biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, NH2, NH(C1-4 alifatski ostatak), N(C1-4 alifatski ostatak)2, OH, =O, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, C1-4-alifatski ostatak i C(=O)-OH.
8. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da
R1 predstavlja parcijalnu strukturu (T1),
[image]
pri čemu
m označava 0, 1, ili 2,
R8a i R8b svaki neovisno jedan od drugoga predstavljaju H, F, Cl, Br, I, O-C1-4 alifatski ostatak ili alifatski ostatak,
R8c označava C1-4 alifatski ostatak, nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, O-C1-4 alifatski ostatak, CF3, i C1-4-alifatski ostatak,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, CF3 i nesupstituiran O-C1-4-alifatski ostatak,
ili označava C3-10-cikloalifatski ostatak, nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, O-C1-4 alifatski ostatak, CF3, i C1-4-alifatski ostatak,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, CF3 i nesupstituiran O-C1-4-alifatski ostatak,
ili označava aril ili heteroaril, svaki puta nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, O-C1-4 alifatski ostatak, OCF3, CF3, CN, C1-4-alifatski ostatak, C(=O)-CH3, C(=O)-C2H5, C(=O)-O-CH3 i C(=O)-O-C2H5, C3-6 cikloalifatski ostatak, 3 do 6 člani heterocikloalifatski ostatak, benzil, fenil, tienil ili piridil,
pri čemu benzil, fenil, tienil i piridil, može svaki puta biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, O-C1-4 alifatski ostatak, OCF3, CF3, CN, C1-4-alifatski ostatak, C(=O)-CH3, C(=O)-C2H5, C(=O)-O-CH3 i C(=O)-O-C2H5, te
pri čemu C3-6 cikloalifatski ostatak i 3 do 6 člani heterocikloalifatski ostatak može svaki puta biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, =O, O-C1-4 alifatski ostatak, OCF3, CF3 C1-4-alifatski ostatak i C(=O)-OH.
9. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da
R7 označava C1-10-alifatski ostatak, nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, OH, O-C1-4-alifatski ostatak, OCF3, SH, SCF3, S-C1-4-alifatski ostatak, C(=O)-O-C1-4-alifatski ostatak, COOH, CF3, CN, i C1-4-alifatski ostatak
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, OCF3, CF3 i nesupstituiran O-C1-4-alifatski ostatak,
ili označava C3-10-cikloalifatski ostatak ili 3 do 10 člani heterocikloalifatski ostatak, svaki puta nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, OH, =O, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, C(=O)-O-C1-4-alifatski ostatak, CF3, CN, C1-4-alifatski ostatak, C3-6 cikloalifatski ostatak, i 3 do 6 člani heterocikloalifatski ostatak,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, OCF3, CF3 i nesupstituiran O-C1-4-alifatski ostatak, te
pri čemu C3-6 cikloalifatski ostatak i 3 do 6 člani heterocikloalifatski ostatak može svaki puta biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, OH, =O, O-C1-4 alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, i C1-4-alifatski ostatak,
i pri čemu C3-10-cikloalifatski ostatak ili 3 do 10 člani heterocikloalifatski ostatak može svaki puta biti proizvoljno premošten preko C1-8 alifatske skupine, koja zauzvrat može biti nesupstituirana ili mono- ili polisupstituirana s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, NO2, OH, O-C1-4 alifatski ostatak, C(=O)-O-C1-4-alifatski ostatak, OCF3, SH, SCF3, S-C1-4 alifatski ostatak, CF3, CN, i C1-4-alifatski ostatak,
pod uvjetom da ako R7 označava 3 do 10 člani heterocikloalifatski ostatak, 3 do 10 člani heterocikloalifatski ostatak je vezan preko ugljikovog atoma.
10. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da
R7 označava C1-8-alifatski ostatak, nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, O-C1-4-alifatski ostatak, COOH, C(=O)-O-C1-4-alifatski ostatak, OCF3, SH, SCF3, S-C1-4-alifatski ostatak, CF3, i C1-4-alifatski ostatak pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, CF3 i nesupstituiran O-C1-4-alifatski ostatak,
ili označava C3-10-cikloalifatski ostatak ili 3 do 10 člani heterocikloalifatski ostatak, svaki puta nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, =O, O-C1-4 alifatski ostatak, OCF3, SCF3, S-C1-4 alifatski ostatak, C(=O)-O-C1-4-alifatski ostatak, CF3, i C1-4-alifatski ostatak,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, OCF3, CF3 i nesupstituiran O-C1-4-alifatski ostatak, i
pri čemu C3-10-cikloalifatski ostatak ili 3 do 10 člani heterocikloalifatski ostatak svaki puta može biti premošten preko nesupstituirane C1-8 alifatske skupine,
pod uvjetom da ako R7 označava 3 do 10 člani heterocikloalifatski ostatak, 3 do 10 člani heterocikloalifatski ostatak je vezan preko ugljikovog atoma.
11. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da
R1 predstavlja parcijalnu strukturu (T1),
[image]
pri čemu
m je 0, 1 ili 2 i
R8a i Rab svaki neovisno jedan od drugoga predstavljaju H, F, O-C1-4 alifatski ostatak ili C1-4 alifatski ostatak;
R8e označava C1-4 alifatski ostatak, nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, nesupstituiran O-C1-4 alifatski ostatak, CF3, i nesupstituiran C1-4-alifatski ostatak,
ili označava C3-10-cikloalifatski ostatak, nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, nesupstituiran O-C1-4 alifatski ostatak, CF3, i nesupstituiran C1-4-alifatski ostatak,
ili
pri čemu
m je 0,
R8a i R8b svaki neovisno jedan od drugoga predstavljaju H, F, O-C1-4 alifatski ostatak ili C1-4 alifatski ostatak; te
R8c označava aril ili heteroaril, svaki puta nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, O-C1-4 alifatski ostatak, OCF3, CF3, CN, C1-4-alifatski ostatak, C(=O)-CH3, C(=O)-C2H5, C(=O)-O-CH3, C(=O)-O-C2H5 i fenil,
pri čemu fenil može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, O-C1-4 alifatski ostatak, OCF3, CF3, CN, C1-4-alifatski ostatak, C(=O)-CH3, C(=O)-C2H5, C(=O)-O-CH3 i C(=O)-O-C2H5,
X predstavlja O ili S;
R2 je odabran iz skupine koja sadrži F; Cl; Br; CF3; CH3; C2H5, iso-propil; ciklopropil; i O-CH3;
R3, R4, R5 i R6 su svaki neovisno jedan od drugoga odabrani iz skupine koja sadrži H; F; Cl; Br; CF3; CN; OCF3 i NO2;
R7 označava C1-6-alifatski ostatak, nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži F, Cl, Br, I, OH, O-C1-4-alifatski ostatak, COOH, C(=O)-O-C1-4-alifatski ostatak, OCF3, SH, SCF3, S-C1-4-alifatski ostatak, CF3, i C1-4-alifatski ostatak,
pri čemu C1-4-alifatski ostatak svaki puta može biti nesupstituiran ili mono- ili polisupstituiran s barem jednim supstituentom odabranim iz skupine koja sadrži OH, i nesupstituiran O-C1-4-alifatski ostatak,
ili označava nesupstituiran C3-6-cikloalifatski ostatak ili nesupstituiran 3 do 6 člani heterocikloalifatski ostatak,
pod uvjetom da ako R7 označava 3 do 6 člani heterocikloalifatski ostatak, 3 do 6 člani heterocikloalifatski ostatak je vezan preko ugljikovog atoma.
12. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je spoj odabran iz skupine koja sadrži:
1 amid N-[(3-Fluorofenil)-metil]-1,4-dimetil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
2 amid 1-Butil-N-[(3-fluorofenil)-metil]-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
3 amid N-[(3-Fluorofenil)-metil]-1,4-dimetil-2-tiokso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
4 amid N-[(3-Fluorofenil)-metil]-1-(2-metoksi-etil)-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
5 amid 1-Etil-N-[(3-fluorofenil)-metil]-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
6 amid N-[(4-Fluorofenil)-metil]-1,4-dimetil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
7 amid N-[(4-Fluorofenil)-metil]-1-(2-metoksi-etil)-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
8 amid 1-Etil-N-[(4-fluorofenil)-metil]-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
9 amid N-[(3-Fluorofenil)-metil]-1,4-dimetil-2-okso-1H-kinolin-3-karboksilne kiseline;
10 amid N-[(3-Fluorofenil)-metil]-1-(2-metoksi-etil)-4-metil-2-okso-1H-kinolin-3-karboksilne kiseline;
11 amid N-[(3-Fluorofenil)-metil]-4-metil-2-okso-1-propil-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
12 amid N-[(3-Fluorofenil)-metil]-4-metil-1-(3-metil-butil)-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
13 amid N-[(3-Fluorofenil)-metil]-4-metil-1-(4-metil-pentil)-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
14 amid N-[(3-Fluorofenil)-metil]-1-(3-metoksi-propil)-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
15 amid N-[(3-Fluorofenil)-metil]-1-[2-(2-metoksi-etoksi)-etil]-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
16 amid 7-Bromo-N-[(3-fluorofenil)-metil]-1,4-dimetil-2-okso-1H-kinolin-3-karboksilne kiseline;
17 amid 7-Bromo-N-[(4-fluorofenil)-metil]-1,4-dimetil-2-okso-1H-kinolin-3-karboksilne kiseline;
18 amid 7-Bromo-N-[(3-fluorofenil)-metil]-1-(2-metoksi-etil)-4-metil-2-okso-1H-kinolin-3-karboksilne kiseline;
19 amid 7-Bromo-N-[(4-fluorofenil)-metil]-1-(2-metoksi-etil)-4-metil-2-okso-1H-kinolin-3-karboksilne kiseline;
20 amid 7-Cijano-N-[(3-fluorofenil)-metil]-1,4-dimetil-2-okso-1H-kinolin-3-karboksilne kiseline;
21 amid 7-Cijano-N-[(4-fluorofenil)-metil]-1,4-dimetil-2-okso-1H-kinolin-3-karboksilne kiseline;
22 amid 7-Cijano-N-[(3-fluorofenil)-metil]-1-(2-metoksi-etil)-4-metil-2-okso-1H-kinolin-3-karboksilne kiseline;
23 amid 7-Cijano-N-[(4-fluorofenil)-metil]-1-(2-metoksi-etil)-4-metil-2-okso-1H-kinolin-3-karboksilne kiseline;
24 amid N-(4,4-Dimetil-pentil)-1-(2-metoksi-etil)-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
25 amid N-(4,4-Dimetil-pentil)-1,4-dimetil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
26 metil ester 2-[3-[(3-Fluorofenil)-metil-karbamoil]-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-1-il]-octene kiseline;
27 metil ester 3-[3-[(3-Fluorofenil)-metil-karbamoil]-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-1-il]-propionske kiseline;
28 2-[3-[(3-Fluorofenil)-metil-karbamoil]-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-1-il]-octena kiselina;
29 3-[3-[(3-Fluorofenil)-metil-karbamoil]-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-1-il]-propionska kiselina;
30 amid N-[(3-Fluorofenil)-metil]-1-[1-(metoksimetil)-propil]-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
31 amid N-[(3-Fluorofenil)-metil]-1-[2-metoksi-1-(metoksimetil)-etil]-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
32 amid N-[(3-Fluorofenil)-metil]-1-(2-metoksi-butil)-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
33 amid N-[(3-Fluorofenil)-metil]-1,4-dimetil-2-okso-7-(trifluorometiloksi)-1H-kinolin-3-karboksilne kiseline;
34 amid 7-Fluoro-N-[(3-fluorofenil)-metil]-1,4-dimetil-2-okso-1H-kinolin-3-karboksilne kiseline;
35 amid N-[(3-Fluorofenil)-metil]-1-(2-metoksi-1-metil-etil)-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
36 amid N-[(4-Fluorofenil)-metil]-1,4-dimetil-2-tiokso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
37 amid 7-Kloro-N-[(3-fluorofenil)-metil]-1,4-dimetil-2-okso-1H-kinolin-3-karboksilne kiseline;
38 amid N-[(3-Fluorofenil)-metil]-1-(2-hidroksi-etil)-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
39 amid 1-(2-Etoksi-etil)-N-[(3-fluorofenil)-metil]-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
40 amid N-[(3-Fluorofenil)-metil]-1-isopropil-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
41 amid N-[(3-Fluorofenil)-metil]-4-metil-2-okso-1-pentil-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
42 amid N-[(3-Fluorofenil)-metil]-1-metil-2-okso-4-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
43 amid N-[(3-Fluorofenil)-metil]-1-(2-metoksi-propil)-4-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
44 amid N-[(3-Fluorofenil)-metil]-4-metil-2-okso-1-tetrahidro-pyran-4-il-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
45 amid N-[(3-Fluorofenil)-metil]-4-metoksi-1-metil-2-okso-7-(trifluorometil)-1H-kinolin-3-karboksilne kiseline;
u odgovarajućem obliku slobodnih spojeva; racemata; enantiomera, dijastereomera, smjesa enantiomera ili dijastereomera u bilo kojem omjeru miješanja ili pojedinačnog enantiomera ili dijastereomera; ili u obliku soli fiziološki prihvatljivih kiselina ili baza.
13. Farmaceutski pripravak naznačen time da sadrži barem jedan spoj prema bilo kojem od prethodnih patentnih zahtjeva
u obliku slobodnih spojeva; racemata; enantiomera, dijastereomera, smjesa enantiomera ili dijastereomera u bilo kojem omjeru miješanja ili u obliku pojedinačnog enantiomera ili dijastereomera; ili u obliku soli fiziološki prihvatljivih kiselina ili baza,
i proizvoljno barem jednu farmaceutski prihvatljivu pomoćnu tvar i/ili proizvoljno barem jedan dodatni aktivni sastojak.
14. Spoj prema bilo kojem od patentnih zahtjeva 1 do 12 naznačen time da je za uporabu za liječenje i/ili profilaksu poremećaja i/ili bolesti odabranih iz skupine koju čine bol, epilepsija, urinarna inkontinencija, anksioznost, ovisnost, manija, bipolarni poremećaji, migrena, kognitivni poremećaji i diskinezije povezane s distonijom.
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 12 naznačen time da je za uporabu za liječenje i/ili profilaksu bola odabranog iz skupine koju čine akutna bol, kronična bol, neuropatska bol, bol u mišićima, visceralna bol i upalna bol.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10008920 | 2010-08-27 | ||
PCT/EP2011/004280 WO2012025239A1 (en) | 2010-08-27 | 2011-08-26 | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators |
EP11754836.2A EP2609086B1 (en) | 2010-08-27 | 2011-08-26 | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150520T1 true HRP20150520T1 (hr) | 2015-07-03 |
Family
ID=43304979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150520TT HRP20150520T1 (hr) | 2010-08-27 | 2015-05-15 | Supstituirani 2-okso- i 2-tiokso-dihidrokinolin-3-karboksamidi kao modulatori kcnq2/3 |
Country Status (30)
Country | Link |
---|---|
US (1) | US8653102B2 (hr) |
EP (1) | EP2609086B1 (hr) |
JP (1) | JP5837934B2 (hr) |
KR (1) | KR101983979B1 (hr) |
CN (1) | CN103189357B (hr) |
AR (1) | AR082731A1 (hr) |
AU (1) | AU2011295408B2 (hr) |
BR (1) | BR112013004690A2 (hr) |
CA (1) | CA2809287C (hr) |
CL (1) | CL2013000542A1 (hr) |
CO (1) | CO6700825A2 (hr) |
CY (1) | CY1116158T1 (hr) |
DK (1) | DK2609086T3 (hr) |
EC (1) | ECSP13012460A (hr) |
ES (1) | ES2537615T3 (hr) |
HK (1) | HK1185346A1 (hr) |
HR (1) | HRP20150520T1 (hr) |
HU (1) | HUE024870T2 (hr) |
IL (1) | IL223820A (hr) |
MX (1) | MX342459B (hr) |
NZ (1) | NZ608697A (hr) |
PE (1) | PE20140214A1 (hr) |
PL (1) | PL2609086T3 (hr) |
PT (1) | PT2609086E (hr) |
RS (1) | RS54002B1 (hr) |
RU (1) | RU2581362C2 (hr) |
SI (1) | SI2609086T1 (hr) |
TW (1) | TWI552750B (hr) |
WO (1) | WO2012025239A1 (hr) |
ZA (1) | ZA201302265B (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011295405B2 (en) * | 2010-08-27 | 2015-01-22 | Grünenthal GmbH | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators |
US9775843B2 (en) | 2012-10-11 | 2017-10-03 | Grünenthal GmbH | Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders |
WO2017120355A1 (en) * | 2016-01-06 | 2017-07-13 | Teva Pharmaceutical Industries Ltd. | Dihydroquinolines and uses thereof |
SG11201905893WA (en) * | 2017-01-23 | 2019-08-27 | Cadent Therapeutics Inc | Potassium channel modulators |
MX2021004647A (es) | 2018-10-22 | 2021-08-16 | Novartis Ag | Formas cristalinas de moduladores de los canales de potasio. |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2513949A1 (de) | 1975-03-29 | 1976-10-07 | Bayer Ag | Azofarbstoffe |
DE2706977A1 (de) | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
FR2482596A1 (fr) | 1980-05-19 | 1981-11-20 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament |
DE3111934A1 (de) | 1981-03-26 | 1982-10-07 | Bayer Ag, 5090 Leverkusen | Oel-in-wasser-emulsionen, verfahren zu deren herstellung und deren verwendung |
FR2509728A1 (fr) | 1981-07-17 | 1983-01-21 | Roussel Uclaf | Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
DE3210063A1 (de) | 1982-03-19 | 1983-09-22 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
DE3211934A1 (de) | 1982-03-31 | 1983-10-13 | Hoechst Ag, 6230 Frankfurt | Salicylsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
FR2532939A1 (fr) | 1982-09-13 | 1984-03-16 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus |
JP3122671B2 (ja) * | 1990-05-23 | 2001-01-09 | 協和醗酵工業株式会社 | 複素環式化合物 |
DE4032147A1 (de) | 1990-10-10 | 1992-04-16 | Bayer Ag | Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung |
US5359365A (en) | 1991-05-24 | 1994-10-25 | Canon Kabushiki Kaisha | Moving image processing method and apparatus |
US6030983A (en) | 1993-06-04 | 2000-02-29 | Ball State University | Lavendamycin analogs, quinoline-5,8-diones and methods of using them |
US5525611A (en) | 1993-06-04 | 1996-06-11 | Behforouz; Mohammad | Lavendamycin analogs and methods of making and using them |
ATE188377T1 (de) | 1993-06-29 | 2000-01-15 | Takeda Chemical Industries Ltd | Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose |
GB9402275D0 (en) * | 1994-02-07 | 1994-03-30 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE9400809D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of quinoline-3-carboxamide compounds |
EP0716077A1 (de) | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
WO1996026925A1 (fr) | 1995-03-01 | 1996-09-06 | Banyu Pharmaceutical Co., Ltd. | Derives de l'arylthioacetamide |
JPH08337583A (ja) * | 1995-04-13 | 1996-12-24 | Takeda Chem Ind Ltd | 複素環化合物およびその製造法 |
DE19738616A1 (de) | 1997-09-04 | 1999-03-11 | Clariant Gmbh | 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel |
GB9807114D0 (en) | 1998-04-02 | 1998-06-03 | Smithkline Beecham Plc | Novel process |
SE9802549D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
JP2000256323A (ja) | 1999-01-08 | 2000-09-19 | Japan Tobacco Inc | 2−オキソキノリン化合物及びその医薬用途 |
AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
WO2001010381A2 (en) | 1999-08-04 | 2001-02-15 | Icagen, Inc. | Methods for treating or preventing pain and anxiety |
EP1208085B1 (en) | 1999-08-04 | 2007-12-05 | Icagen, Inc. | Benzanilides as potassium channel openers |
US6395750B1 (en) | 1999-10-25 | 2002-05-28 | Active Biotech Ab | Drugs for the treatment of malignant tumors |
ES2330719T3 (es) * | 2000-12-28 | 2009-12-15 | SHIONOGI & CO., LTD. | Derivados de 2-piridona con afinidad para el receptor cannabinoide de tipo 2. |
JP2005507853A (ja) | 2001-02-20 | 2005-03-24 | ブリストル−マイヤーズ スクイブ カンパニー | Kcnqカリウムチャンネルモジュレーター並びに片頭痛および機構的に関連する疾患の治療におけるそれらの使用 |
HUP0303841A2 (hu) | 2001-02-20 | 2004-03-01 | Bristol-Myers Squibb Company | 2,4-Diszubsztituált-5-pirimidinkarboxamid-származékok mint KCNQ káliumcsatorna modulátorok és ezeket tartalmazó gyógyszerkészítmények és előállításuk |
US6593349B2 (en) | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
WO2002081728A2 (en) | 2001-04-06 | 2002-10-17 | Smithkline Beecham Corporation | Quinoline inhibitors of hyak1 and hyak3 kinases |
MXPA05002914A (es) | 2002-09-17 | 2005-05-27 | Pharmacia Corp | Moduladores de los receptores x hepaticos aromaticos. |
WO2004026819A2 (en) | 2002-09-18 | 2004-04-01 | The Curators Of The University Of Missouri | OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR |
US20040198724A1 (en) | 2002-12-23 | 2004-10-07 | Icagen, Inc. | Quinazolinones as potassium channel modulators |
EP1449841A1 (en) | 2003-02-19 | 2004-08-25 | Bayer CropScience SA | New fungicidal compounds |
EP1604983A4 (en) | 2003-03-17 | 2008-06-25 | Takeda Pharmaceutical | Receptor Antagonists |
EP1680411A2 (en) | 2003-10-08 | 2006-07-19 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
CA2545092C (en) | 2003-11-24 | 2010-08-17 | Pfizer Inc. | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity |
AR048669A1 (es) | 2004-03-03 | 2006-05-17 | Syngenta Ltd | Derivados biciclicos de bisamida |
JP4054369B2 (ja) | 2004-05-04 | 2008-02-27 | ファイザー株式会社 | オルト置換アリールまたはヘテロアリールアミド化合物 |
WO2006051311A1 (en) | 2004-11-12 | 2006-05-18 | Galapagos Nv | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
EP1861394A1 (en) | 2005-03-03 | 2007-12-05 | H.Lundbeck A/S | Substituted pyridine derivatives |
DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
WO2007015767A1 (en) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | Pyridine derivatives as dipeptedyl peptidase inhibitors |
CN101277939A (zh) | 2005-09-09 | 2008-10-01 | 布里斯托尔-迈尔斯斯奎布公司 | 无环ikur抑制剂 |
EP1951685A1 (en) | 2005-11-18 | 2008-08-06 | NeuroSearch A/S | Novel quinazoline derivatives and their medical use |
JP5202327B2 (ja) | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
CN104138634B (zh) | 2006-04-13 | 2016-09-07 | 梯瓦制药国际有限责任公司 | 递送抗偏头痛化合物的透皮方法和系统 |
US7763607B2 (en) * | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
WO2007133637A2 (en) | 2006-05-10 | 2007-11-22 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
JP2009542798A (ja) | 2006-07-11 | 2009-12-03 | ファイザー株式会社 | 置換n−二環式アルキル二環式カルボキシアミド化合物 |
DE602007004638D1 (de) | 2006-07-20 | 2010-03-18 | Amgen Inc | Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin |
CA2658190C (en) | 2006-07-20 | 2013-01-29 | Amgen Inc. | Di-amino-substituted heterocyclic compounds and methods of use |
WO2008014307A2 (en) | 2006-07-26 | 2008-01-31 | Novartis Ag | Inhibitors of undecaprenyl pyrophosphate synthase |
US20100022589A1 (en) | 2006-07-27 | 2010-01-28 | Mccoull William | Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
US20110130397A1 (en) * | 2006-09-22 | 2011-06-02 | Soongyu Choi | Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof |
DE102006049452A1 (de) | 2006-10-17 | 2008-05-08 | Grünenthal GmbH | Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln |
JP2010512305A (ja) | 2006-10-23 | 2010-04-22 | ファイザー株式会社 | 置換フェニルメチルビシクロカルボキシアミド化合物 |
WO2008097976A1 (en) | 2007-02-09 | 2008-08-14 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
US9162984B2 (en) | 2007-03-30 | 2015-10-20 | University Of Rochester | Small-molecule modulators of melanin expression |
US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
BRPI0814758A2 (pt) | 2007-08-03 | 2015-03-03 | Hoffmann La Roche | Piridinacarboxamida e derivados de benzamida como ligantes taar1 |
CA2702469A1 (en) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Ccr10 antagonists |
US8119656B2 (en) * | 2007-12-07 | 2012-02-21 | The Board Of Regents Of The University Of Texas System | Inhibitors of the influenza virus non-structural 1 protein |
AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
US8513295B2 (en) | 2008-09-23 | 2013-08-20 | Georgetown University | Viral and fungal inhibitors |
DK2350093T3 (da) | 2008-10-24 | 2012-11-12 | Gruenenthal Gmbh | Substituerede 4,5,6,7-tetrahydrothienopyridiner som KCNQ2/3-modulatorer til behandling af smerte, epilepsi og urininkontinens. |
US8367700B2 (en) | 2008-12-17 | 2013-02-05 | Gruenenthal Gmbh | Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators |
WO2010094645A1 (en) | 2009-02-17 | 2010-08-26 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
WO2010094644A1 (en) | 2009-02-17 | 2010-08-26 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
TWI504395B (zh) | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
WO2010102778A2 (de) | 2009-03-10 | 2010-09-16 | Grünenthal GmbH | Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren |
TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
TW201038565A (en) | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
TWI461197B (zh) | 2009-03-12 | 2014-11-21 | 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier | |
AU2011295407B2 (en) | 2010-08-27 | 2016-01-21 | Grunenthal Gmbh | Substituted quinoline-3-carboxamides as KCNQ2/3 modulators |
AU2011295405B2 (en) * | 2010-08-27 | 2015-01-22 | Grünenthal GmbH | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators |
-
2011
- 2011-08-26 PE PE2013000317A patent/PE20140214A1/es active IP Right Grant
- 2011-08-26 TW TW100130611A patent/TWI552750B/zh not_active IP Right Cessation
- 2011-08-26 US US13/218,579 patent/US8653102B2/en not_active Expired - Fee Related
- 2011-08-26 NZ NZ608697A patent/NZ608697A/en not_active IP Right Cessation
- 2011-08-26 AR ARP110103116A patent/AR082731A1/es active IP Right Grant
- 2011-08-26 KR KR1020137007666A patent/KR101983979B1/ko active IP Right Grant
- 2011-08-26 RU RU2013113301/04A patent/RU2581362C2/ru not_active IP Right Cessation
- 2011-08-26 PL PL11754836T patent/PL2609086T3/pl unknown
- 2011-08-26 HU HUE11754836A patent/HUE024870T2/en unknown
- 2011-08-26 CA CA2809287A patent/CA2809287C/en not_active Expired - Fee Related
- 2011-08-26 SI SI201130428T patent/SI2609086T1/sl unknown
- 2011-08-26 JP JP2013525189A patent/JP5837934B2/ja not_active Expired - Fee Related
- 2011-08-26 PT PT117548362T patent/PT2609086E/pt unknown
- 2011-08-26 DK DK11754836T patent/DK2609086T3/da active
- 2011-08-26 RS RS20150338A patent/RS54002B1/en unknown
- 2011-08-26 AU AU2011295408A patent/AU2011295408B2/en not_active Ceased
- 2011-08-26 CN CN201180041440.6A patent/CN103189357B/zh not_active Expired - Fee Related
- 2011-08-26 MX MX2013002119A patent/MX342459B/es active IP Right Grant
- 2011-08-26 ES ES11754836.2T patent/ES2537615T3/es active Active
- 2011-08-26 EP EP11754836.2A patent/EP2609086B1/en active Active
- 2011-08-26 BR BR112013004690A patent/BR112013004690A2/pt not_active IP Right Cessation
- 2011-08-26 WO PCT/EP2011/004280 patent/WO2012025239A1/en active Application Filing
-
2012
- 2012-12-24 IL IL223820A patent/IL223820A/en active IP Right Grant
-
2013
- 2013-02-25 CO CO13037611A patent/CO6700825A2/es unknown
- 2013-02-25 CL CL2013000542A patent/CL2013000542A1/es unknown
- 2013-02-26 EC ECSP13012460 patent/ECSP13012460A/es unknown
- 2013-03-26 ZA ZA2013/02265A patent/ZA201302265B/en unknown
- 2013-11-13 HK HK13112723.4A patent/HK1185346A1/xx not_active IP Right Cessation
-
2015
- 2015-03-31 CY CY20151100316T patent/CY1116158T1/el unknown
- 2015-05-15 HR HRP20150520TT patent/HRP20150520T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150520T1 (hr) | Supstituirani 2-okso- i 2-tiokso-dihidrokinolin-3-karboksamidi kao modulatori kcnq2/3 | |
HRP20150526T1 (hr) | Supstituirani 2-oksi-kinolin-3-karboksamidi kao modulatori kcnq2/3 | |
JP2014502979A5 (hr) | ||
JP2012521428A5 (hr) | ||
NZ593030A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
JP2012521429A5 (hr) | ||
JP2007505889A (ja) | アルファ−2−デルタリガンドとアセチルコリンステラーゼ阻害物質 | |
HRP20120505T1 (hr) | Supstituirani n fenilmetil oksoprolin amidi kao antagonisti receptora p x i postupci njihove upotrebe | |
RU2016104844A (ru) | Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора | |
JP2005536475A5 (hr) | ||
US20080261958A1 (en) | Combination of Organic Compounds | |
US20230012615A1 (en) | Methods for treatment of fibrotic diseases | |
JP5599115B2 (ja) | 2−オキソ−1−ピロリジン誘導体を含む医薬組成物 | |
KR20160093000A (ko) | 창자 과투과성을 치료하기 위한 티로신 하이드록실라제 억제제 | |
JP2003502308A5 (hr) | ||
RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
RU2009148507A (ru) | Производное тетрагидроизохинолин-1-она или его соль | |
RU2012120759A (ru) | Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы | |
JP2013522368A5 (hr) | ||
JP2013538218A5 (hr) | ||
HK1141019A1 (en) | Carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound | |
KR20110118830A (ko) | Nk 수용체 길항제의 용도 | |
EA201270653A1 (ru) | Антагонист dpи его применение | |
RU2015101211A (ru) | Производное имидазопиридина, используемое для лечения сахарного диабета | |
RU2009142595A (ru) | Новые соединения для лечения психических расстройств, их получение и применение |